← All indications
Geographic Atrophy
A form of MACULAR DEGENERATION also known as dry macular degeneration marked by occurrence of a well-defined progressive lesion or atrophy in the central part of the RETINA called the MACULA LUTEA. It is distinguishable from WET MACULAR DEGENERATION in that the latter involves neovascular exudates.
Drugs by status
Approved for this indication (1)
Phase 3 trials (10)
Phase 2 trials (32)
- brimonidine
- clg561
- cnto 2476
- prednisone
- n-(4-hydroxyphenyl)all-trans retinamide
- gsk-933776
- lfg316
- opregen
- ot-551
- compstatin
- lidocaine
- sitagliptin
- sirolimus
- aavcagscd59
- embryonic stem cell-derived rpe cells
- triamcinolone
- dapagliflozin
- sodium chloride
- onl1204
- fb-lrx
- ro7171009
- gt005
- ngm621
- gem103
- danicopan
- voy-101
- bi 1584862
- bi 771716
- ocu410
- eyecyte
- +2 more
Phase 1 trials (4)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (12)
Organization Involved with Phase 2 Indications (32)
- Alimera Sciences
- Lineage Therapeutics
- Sirion Therapeutics
- Genentech
- Pfizer
- Alexion
- Allegro Ophthalmics, LLC
- Allergan
- Santen Inc.
- GlaxoSmithKline
- Hemera Biosciences
- Ionis Pharmaceuticals, Inc.
- NGM Biopharmaceuticals, Inc
- Othera Pharmaceuticals
- Stealth BioTherapeutics Inc.
- StemCells, Inc.
- The EMMES Corporation
- National Eye Institute (NEI)
- Snyder, Robert W., M.D., Ph.D., P.C.
- University of Pennsylvania
- University of Miami
- Tel Aviv University
- University of California, San Francisco
- Annexon
- Regenerative Patch Technologies
- Hebrew University
- Department of Veteran Affairs
- ReVision Therapeutics, Inc.
- Johnson and Johnson
- Assistance Publique - Hôpitaux de Paris
- +2 more
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (2)